Product Description
digluconate chlorhexidine mouthwash for the prevention of alveolar osteitis following third molar extraction (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02382809)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pierre Fabre
Company Location: Europe
Company Founding Year: 1962
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Osteitis|Dry Socket
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2014-004682-24 |
2014-004682-24 | P4 |
Completed |
Osteitis |
2016-02-17 |
2025-06-28 |
Treatments |
|
NCT02382809 |
DC0071 BB 4 05 | P4 |
Completed |
Osteitis|Dry Socket |
2016-02-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|